What is LevitasBio?
LevitasBio specializes in advanced sample preparation and characterization tools utilizing levitation technology, aimed at enhancing research outcomes for complex biological samples. Their product lineup includes the LeviCell systems for cell enrichment and isolation, LeviPrep for tissue processing, and LeviMetrics for sample analysis. The company targets clients in the life sciences sector, including academic institutions and research facilities, focusing on applications such as single-cell genomics, cancer profiling, and 3D culture modeling. LevitasBio's innovative solutions are designed to improve sample viability and throughput while reducing costs, making them essential for modern scientific research. By addressing critical bottlenecks in laboratory workflows, the company has established a robust market position as a provider of high-precision instrumentation.
How much funding has LevitasBio raised?
LevitasBio has raised a total of $61M across 3 funding rounds:
Series A
$8M
Series B
$18M
Series C
$35M
Series A (2017): $8M with participation from Decheng Capital
Series B (2021): $18M led by Thalys Medical and Decheng Capital
Series C (2022): $35M supported by Pavilion Capital, Decheng Capital, and Novalis LifeSciences
Key Investors in LevitasBio
Pavilion Capital
Pavilion Capital Partners is a growth-oriented private equity investor providing capital and strategic support to fast-growing companies in the United States and Asia.
Decheng Capital
Decheng Capital is a global investment firm specializing in providing capital and strategic support to early-stage life science and growth-stage healthcare companies.
Novalis LifeSciences
Novalis LifeSciences LLC is a boutique investment and advisory firm focused on the life science industry, specializing in venture capital for tools, diagnostics, and biopharma therapeutics.
What's next for LevitasBio?
With this latest infusion of capital, LevitasBio is well-positioned to accelerate its commercial expansion and deepen its research and development capabilities. The company's trajectory, marked by consistent growth from its Series A through its current enterprise-level funding, suggests a focus on scaling manufacturing and broadening its global distribution network. As the demand for high-throughput, single-cell analysis continues to rise, LevitasBio is expected to leverage its proprietary levitation technology to capture a larger share of the life sciences tools market. Future strategic initiatives will likely prioritize the integration of its LeviMetrics platform into broader clinical workflows, further cementing its status as an indispensable partner for research facilities and biopharma innovators worldwide.
See full LevitasBio company page
